STERIS plc (Ireland)

Valuation Analysis

About the Company

STERIS plc (Ireland) en bref

STERIS plc (Ireland) (STE) is currently trading at 176,48 € with a market capitalization of 17,2 Md €. The trailing P/E ratio stands at 25.53x, with a forward P/E of 16.72x. The 52-week range spans from 170,12 € to 234,89 €; the current price is 24.9% below the yearly high. Year-over-year revenue growth stands at +7.3%. The net profit margin stands at 13.18%.

💰 Dividende

STERIS plc (Ireland) pays an annual dividend of 2,20 € per share, representing a yield of 1.24%. The payout ratio stands at 31.02%.

📊 Avis des analystes

7 analystes évaluent STERIS plc (Ireland) (STE) au consensus : Acheter. L'objectif de cours moyen est de 223,92 €, soit un potentiel de +26.88% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 196,15 € à 244,09 €.

STERIS plc (Ireland) : la thèse d'investissement en détail

STERIS plc (Ireland) (STE) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 52.2% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. The combination of a 44.24% gross margin and 20.04% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Wall Street consensus sits at Buy with an average price target implying roughly 26.88% upside from current levels — analyst sentiment is firmly constructive.

Valorisation en contexte

The PEG ratio at 1.4 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

À surveiller

• The forward P/E of 16.72x is meaningfully below the trailing 25.53x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 26.88% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy STERIS plc (Ireland)?

Compare top-rated brokers — low fees, trusted providers, fully regulated.